MBX Biosciences MBX Institutional Ownership

MBX Biosciences, Inc. (NASDAQ:MBX) has 173 institutional investors that have filed 13F reports for the period ending June 2026.

• These investors held 116.8% of outstanding shares in June 2026, up from 112.8% in March 2026.
• Their total shares held in MBX increased 9.83% from the prior quarter, while the number of investors in MBX Biosciences increased 98.85% year over year.
• Activity in MBX broke down as 102 buyers, 50 sellers, and 21 unchanged among 173 total holders.
• Institutional investors collectively held 55.71Mn shares in MBX Biosciences as of June 2026, up by 4.99Mn shares quarter on quarter, and up 18.44Mn shares year over year.
• As of June 30, 2026, Frazier Life Sciences Management, L.P. held the largest stake in MBX Biosciences with 6.65Mn shares, accounting for 13.95% of total shares outstanding.
• The largest buyers of MBX Biosciences for the quarter ending June 2026 were Paradigm Biocapital Advisors LP (2.51Mn), FMR LLC (2.39Mn), WELLINGTON MANAGEMENT GROUP LLP (1.79Mn), BlackRock, Inc. (382.27K), MARSHALL WACE, LLP (339.18K).
• The largest sales of MBX for the quarter ending June 2026 came from Deep Track Capital, LP (1.02Mn), BRAIDWELL LP (781.59K), Caligan Partners LP (648.59K), Cormorant Asset Management, LP (570.0K), EcoR1 Capital, LLC (388.5K).
• Business Quant data shows the 10 biggest positions in MBX Biosciences as of June 2026 are held by Frazier Life Sciences Management, L.P. (6.65Mn), FMR LLC (5.32Mn), WELLINGTON MANAGEMENT GROUP LLP (4.98Mn), NEA Management Company, LLC (3.61Mn), ORBIMED ADVISORS LLC (3.43Mn), BlackRock, Inc. (3.32Mn), Paradigm Biocapital Advisors LP (2.51Mn), NVP Associates, LLC (2.14Mn), Deep Track Capital, LP (1.73Mn), Polar Capital Holdings Plc (1.61Mn).